<document id="DDI-DrugBank.d207">
    <sentence id="DDI-DrugBank.d207.s1" text="In patients receiving a potent CYP3A4 inducer such as rifampicin or phenytoin, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).">
        <entity charOffset="54-63" id="DDI-DrugBank.d207.s1.e0" text="rifampicin" type="drug" />
        <entity charOffset="68-76" id="DDI-DrugBank.d207.s1.e1" text="phenytoin" type="drug" />
        <pair ddi="false" e1="DDI-DrugBank.d207.s1.e0" e2="DDI-DrugBank.d207.s1.e1" id="DDI-DrugBank.d207.s1.p0" />
    </sentence>
    <sentence id="DDI-DrugBank.d207.s2" text="International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.">
        <entity charOffset="114-121" id="DDI-DrugBank.d207.s2.e0" text="warfarin" type="drug" />
        <entity charOffset="132-137" id="DDI-DrugBank.d207.s2.e1" text="IRESSA" type="brand" />
        <pair ddi="true" e1="DDI-DrugBank.d207.s2.e0" e2="DDI-DrugBank.d207.s2.e1" id="DDI-DrugBank.d207.s2.p0" type="effect" />
    </sentence>
    </document>